Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer

Investigational New Drugs

Volumn 33, Issue 4, 2015, Pages 848-860

  Collery, Philippe ^a   Mohsen, Ahmed ^b   Kermagoret, Anthony ^b   Corre, Samantha ^c   Bastian, Gérard ^d   Tomas, Alain ^e   Wei, Ming ^f   Santoni, François ^g   Guerra, Nadia ^c   Desmaële, Didier ^b   D'Angelo, Jean ^b  

^a Société de Coordination de Recherches Thérapeutiques   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^g Laboratoire de l'Office d'Equipement Hydraulique de Corse   (France)

Author keywords

Bioluminescence; Breast cancer; MDA MB231 cell line; Rhenium; Selenium

Indexed keywords

9 METHYLGUANINE; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; RHENIUM DISELENOETHER COMPLEX; UNCLASSIFIED DRUG; 9-METHYLGUANINE; ANTINEOPLASTIC AGENT; COORDINATION COMPOUND; GUANINE; RHENIUM; SELENIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NUDE MOUSE; PATHOLOGY; SECONDARY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COORDINATION COMPLEXES; FEMALE; GUANINE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, NUDE; RHENIUM; SELENIUM; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84942984941     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0265-z     Document Type: Article

References (67)

1. Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic anticancer compounds. J Med Chem 54(1):3-25. doi:10.1021/jm100020w
2. Leonidova A, Gasser G (2014) Underestimated potential of organometallic rhenium complexes as anticancer agents. ACS Chem Biol 9(10):2180-2193. doi:10.1021/cb500528c
3. Parson C, Smith V, Krauss C, Banerjee HN, Reilly C, Krause JA, Wachira JM, Giri D, Winstead A, Mandal SK (2014) Anticancer properties of novel rhenium pentylcarbanato compounds against MDA-MB-468(HTB-132) triple node negative human breast cancer cell lines. Br J Pharm Res 4(3):362-367. doi:10.9734/BJPR/2014/4697
4. Fernandez-Herrera MA, Sandoval-Ramirez J, Sanchez-Sanchez L, Lopez-Munoz H, Escobar-Sanchez ML (2014) Probing the selective antitumor activity of 22-oxo-26-selenocyanocholestane derivatives. Eur J Med Chem 74:451-460. doi:10.1016/j.ejmech.2013.12.059
5. Guo P, Zhao P, Liu J, Ma H, Bai J, Cao Y, Liu Y, He H, Qi C (2013) Preparation of a novel organoselenium compound and its anticancer effects on cervical cancer cell line HeLa. Biol Trace Elem Res 151(2):301-306. doi:10.1007/s12011-012-9563-x
6. Ibanez E, Plano D, Font M, Calvo A, Prior C, Palop JA, Sanmartin C (2011) Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates. Eur J Med Chem 46(1):265-274. doi:10.1016/j.ejmech.2010.11.013
7. Wallenberg M, Misra S, Bjornstedt M (2014) Selenium cytotoxicity in cancer. Basic Clin Pharmacol 114(5):377-386. doi:10.1111/bcpt.12207
8. Kermagoret A, Morgant G, D'Angelo J, Tomas A, Roussel P, Bastian G, Collery P, Desmaële D (2011) Synthesis, structural characterization and biological activity against several human tumor cell lines of four rhenium(I) diseleno-ethers complexes: Re(CO)3Cl(PhSe(CH2)2SePh), Re(CO)3Cl(PhSe(CH2)3SePh), Re(CO)3Cl(HO2C-CH2Se(CH2)2SeCH2-CO2H) and Re(CO)3Cl(HO2C-CH2Se(CH2)3SeCH2-CO2H). Polyhedron 30:347-354
9. Collery P, Bastian G, Santoni S, Mohsen A, Wei M, Collery T, Tomas A, Desmaele D, d'Angelo J (2014) Uptake and efflux of rhenium in cells exposed to rhenium diseleno-ether and tissue distribution of rhenium and selenium after rhenium diseleno-ether treatment in mice. Anticancer Res 34(4):1679-1690
10. Collery P, Mohsen A, Kermagoret A, d'Angelo J, Morgant G, Desmaele D, Tomas A, Collery T, Wei M, Badawi A (2012) Combination of Three Metals for the Treatment of Cancer: Gallium, Rhenium and Platinum. 1- Determination of the Optimal Schedule of Treatment. Anticancer Res 32(7):2769-2782
11. Walker MK, Boberg JR, Walsh MT, Wolf V, Trujillo A, Duke MS, Palme R, Felton LA (2012) A less stressful alternative to oral gavage for pharmacological and toxicological studies in mice. Toxicol Appl Pharmacol 260(1):65-69. doi:10.1016/j.taap.2012.01.025
12. Uehara T, Koike M, Nakata H, Miyamoto S, Motoishi S, Hashimoto K, Oku N, Nakayama M, Arano Y (2003) In vivo recognition of cyclopentadienyltricarbonylrhenium (CpTR) derivatives. Nucl Med Biol 30(3):327-334
13. Novotny L, Rauko P, Kombian SB, Edafiogho IO (2010) Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 57(5):383-391
14. Desai D, Kaushal N, Gandhi UH, Arner RJ, D'Souza C, Chen G, Vunta H, El-Bayoumy K, Amin S, Prabhu KS (2010) Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact 188(3):446-456. doi:10.1016/j.cbi.2010.09.021
15. Facompre ND, El-Bayoumy K, Sun YW, Pinto JT, Sinha R (2010) 1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prev Res (Phila) 3(8):975-984. doi:10.1158/1940-6207.CAPR-10-0054
16. Facompre ND, Sinha I, El-Bayoumy K, Pinto JT, Sinha R (2012) Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. Int J Cancer 131(9):2134-2142. doi:10.1002/ijc.27468
17. Sanmartin C, Plano D, Font M, Palop JA (2011) Kinase regulation by sulfur and selenium containing compounds. Curr Cancer Drug Targets 11(4):496-523
18. Moreno E, Plano D, Lamberto I, Font M, Encio I, Palop JA, Sanmartin C (2012) Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro. Eur J Med Chem 47(1):283-298. doi:10.1016/j.ejmech.2011.10.056
19. Sanmartin C, Plano D, Sharma AK, Palop JA (2012) Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. Int J Mol Sci 13(8):9649-9672. doi:10.3390/ijms13089649
20. 3]+core. Inorg Chem 43(6): 2087-2096. doi:10.1021/ic035012a
21. Zobi F, Spingler B, Alberto R (2005) Guanine and plasmid DNA binding of mono- and trinuclear fac-[Re(CO)3]+complexes with amino acid ligands. Chembiochem 6(8):1397-1405. doi:10.1002/ cbic.200400453
22. Ho J, Lee WY, Koh KJ, Lee PP, Yan YK (2013) Rhenium(I) tricarbonyl complexes of salicylaldehyde semicarbazones: synthesis, crystal structures and cytotoxicity. J Inorg Biochem 119:10-20. doi:10.1016/j.jinorgbio.2012.10.011
23. Shtemenko N, Collery Ph, Shtemenko A (2006) Synergistic effect of cisplatin and cis-rhenium (III) diadamantate on tumor growth. In:Alpoim M C, Vasconcellos Morais P, Santos M A, Cristovao A J, Centeno J A, Collery P H (ed) Metal Ions in Biology and Medicine John Libbey Eurotext, Paris 9:374-381
24. Shtemenko N, Collery P, Shtemenko A (2007) Dichlorotetra-μisobutyratodirhenium (III): enhancement of cisplatin action and RBC-stabilizing properties. Anticancer Res 27:2487-2492
25. Shtemenko AV, Collery P, Shtemenko NI, Domasevitch KV, Zabitskaya ED, Golichenko AA (2009) Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin. Dalton Trans 26: 5132-5136. doi:10.1039/b821041a
26. Zobi F, Blacque O, Sigel RK, Alberto R (2007) Binding interaction of [Re(H2O)3(CO)3]+with the DNA fragment d(CpGpG). Inorg Chem 46(25):10458-10460. doi:10.1021/ic701647m
27. Zobi F, Spingler B (2012) Post-protein-binding reactivity and modifications of the fac-[Re(CO)3]+core. Inorg Chem 51(3):1210-1212. doi:10.1021/ic2023314
28. Prater ME, Mindiola DJ, Ouyang X, Dunbar KR (1998) A quadruply-bonded dirhenium complex bridged by two N1/N6 adenate ligands. Inorg Chem Commun 1:475-477
29. Adams KM, Marzilli LG (2007) fac-[Re(CO)3(H2O)3]+nucleoside monophosphate adducts investigated in aqueous solution by multinuclear NMR spectroscopy. Inorg Chem 46(12):4926-4936. doi:10.1021/ic062410f
30. Adams KM, Marzilli PA, Marzilli LG (2007) Reactions of fac-[Re(CO)3(H2O)3]+with nucleoside diphosphates and thiamine diphosphate in aqueous solution investigated by multinuclear NMR spectroscopy. Inorg Chem 46(22):9172-9181. doi:10.1021/ic701038f
31. Mencalha A, Victorino VJ, Cecchini R, Panis C (2014) Mapping oxidative changes in breast cancer: understanding the basic to reach the clinics. Anticancer Res 34(3):1127-1140
32. Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, Simao AN, Barbosa DS, Pinge-Filho P, Cecchini R, Cecchini AL (2012) Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat 133(3):881-888. doi:10.1007/s10549-011-1851-1
33. Herrera AC, Panis C, Victorino VJ, Campos FC, Colado-Simao AN, Cecchini AL, Cecchini R (2012) Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol Immunother 61(11):2193-2201. doi:10.1007/s00262-012-1283-8
34. Kim J, Mizokami A, Shin M, Izumi K, Konaka H, Kadono Y, Kitagawa Y, Keller ET, Zhang J, Namiki M (2014) SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. Anticancer Res 34(6):2821-2831
35. Pons DG, Sastre-Serra J, Nadal-Serrano M, Oliver A, Garcia-Bonafe M, Bover I, Roca P, Oliver J (2012) Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer. Anticancer Res 32(11): 4723-4728
36. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simao AN, Cecchini AL, Cecchini R (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133(1):89-97. doi:10.1007/s10549-011-1693-x
37. Lee KH, Jeong D (2012) Bimodal actions of selenium essential for antioxidant and toxic pro-oxidant activities: the selenium paradox (review). Mol Med Rep 5(2):299-304. doi:10.3892/mmr.2011.651
38. Jamier V, Ba LA, Jacob C (2010) Selenium- and tellurium-containing multifunctional redox agents as biochemical redox modulators with selective cytotoxicity. Chem Eur J 16(36):10920-10928. doi:10.1002/chem.201000884
39. Park E-M, Choi K-S, Park S-Y, Kong E-S, Zu K, Wu Y, Zhang H, Ip C, Y-M P (2005) A display thiol-proteomics approach to characterize global redox modification of proteins by selenium: implications for the anticancer action of selenium. Cancer Genomics Proteomics 2:25-36
40. Huang Z, Rose AH, Hoffmann PR (2012) The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16(7):705-743. doi:10.1089/ars.2011.4145
41. Duntas LH (2009) Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm Metab Res 41(6):443-447. doi:10.1055/s-0029-1220724
42. Poplawska B, Bielawska A, Surazynski A, Czarnomysy R, Bielawski K (2009) Novel dinuclear platinum(II) complexes targets NFkappaB signaling pathway to induce apoptosis and inhibit metabolism of MCF-7 breast cancer cells. Folia Histochem Cytobiol 47(5):S141-S146. doi:10.2478/v10042-009-0084-1
43. Kretz-Remy C, Arrigo AP (2001) Selenium: a key element that controls NF-kappa B activation and I kappa B alpha half life. Biofactors 14(1-4):117-125
44. Youn HS, Lim HJ, Choi YJ, Lee JY, Lee MY, Ryu JH (2008) Selenium suppresses the activation of transcription factor NF-kappa B and IRF3 induced by TLR3 or TLR4 agonists. Int Immunopharmacol 8(3):495-501. doi:10.1016/j.intimp.2007.12.008
45. Shigdar S, Li Y, Bhattacharya S, O'Connor M, Pu C, Lin J, Wang T, Xiang D, Kong L, Wei MQ, Zhu Y, Zhou S, Duan W (2014) Inflammation and cancer stem cells. Cancer Lett 345(2):271-278. doi:10.1016/j.canlet.2013.07.031
46. Petrie HT, Klassen LW, Kay HD (1989) Selenium and the immune response: 1. Modulation of alloreactive human lymphocyte functions in vitro. J Leukoc Biol 45(3):207-214
47. Arthur JR, McKenzie RC, Beckett GJ (2003) Selenium in the immune system. J Nutr 133(5 Suppl 1):1457S-1459S
48. Broome CS, McArdle F, Kyle JA, Andrews F, Lowe NM, Hart CA, Arthur JR, Jackson MJ (2004) An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr 80(1):154-162
49. Petrie HT, Klassen LW, Klassen PS, O'Dell JR, Kay HD (1989) Selenium and the immune response: 2. Enhancement of murine cytotoxic T-lymphocyte and natural killer cell cytotoxicity in vivo. J Leukoc Biol 45(3):215-220
50. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G (1996) Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells. Biol Trace Elem Res 52(3):227-239. doi:10.1007/BF02789164
51. Kiremidjian-Schumacher L, Roy M (1998) Selenium and immune function. Z Ernaehrungswiss 37(Suppl 1):50-56
52. Hagemann-Jensen M, Uhlenbrock F, Kehlet S, Andresen L, Gabel-Jensen C, Ellgaard L, Gammelgaard B, Skov S (2014) The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem 289(45):31576-31590. doi:10.1074/jbc.M114.591537
53. Bae DS, Hwang YK, Lee JK (2012) Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell Immunol 276(1-2):122-127. doi:10.1016/j.cellimm.2012.04.011
54. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ (2003) NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 4(6):557-564. doi:10.1038/ni929
55. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12:24. doi:10.1186/1471-2407-12-24
56. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS (2005) Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 175(12):7819-7828
57. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413-441. doi:10.1146/annurev-immunol-032712-095951
58. Zafirova B, Wensveen FM, Gulin M, Polic B (2011) Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 68(21):3519-3529. doi:10.1007/s00018-011-0797-0
59. Shrimali RK, Irons RD, Carlson BA, Sano Y, Gladyshev VN, Park JM, Hatfield DL (2008) Selenoproteins mediate T cell immunity through an antioxidant mechanism. J Biol Chem 283(29):20181-20185. doi:10.1074/jbc.M802559200
60. Vunta H, Belda BJ, Arner RJ, Channa Reddy C, Vanden Heuvel JP, Sandeep Prabhu K (2008) Selenium attenuates pro-inflammatory gene expression in macrophages. Mol Nutr Food Res 52(11): 1316-1323. doi:10.1002/mnfr.200700346
61. Plano D, Ibanez E, Calvo A, Palop JA, Sanmartin C (2011) Novel library of selenocompounds as kinase modulators. Molecules 16(8): 6349-6364. doi:10.3390/molecules16086349
62. Ibanez E, Agliano A, Prior C, Nguewa P, Redrado M, Gonzalez-Zubeldia I, Plano D, Palop AJ, Sanmartin C, Calvo A (2012) The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. Curr Med Chem 19(1):3031-3043
63. Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, Hoffman RM, Seshadri M (2011) Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and antitumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Res 31(2):387-393
64. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG (2009) Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118(1):33-43. doi:10.1007/s10549-008-0216-x
65. Chen YC, Prabhu KS, Mastro AM (2013) Is selenium a potential treatment for cancer metastasis? Nutrients 5(4):1149-1168. doi:10.3390/nu5041149
66. Franca CA, Nogueira CR, Ramalho A, Carvalho AC, Vieira SL, Penna AB (2011) Serum levels of selenium in patients with breast cancer before and after treatment of external beam radiotherapy. Ann Oncol 22(5):1109-1112. doi:10.1093/annonc/mdq547
67. Collery P, D'Angelo J, Morgant G (2015) Rhenium complexes and their pharmaceutical use. Eur Patent 2575800